Physio-Control signs consent decree with FDA on QA issues:
This article was originally published in Clinica
Executive Summary
Physio-Control, a Medtronic subsidiary and developer of external defibrillators, has agreed with the US FDA on a plan that would resolve quality issues at its Redmond, Washington facility and enable the company to resume US distribution of its products. Medtronic suspended US shipments of the defibrillators from the plant in January 2007 (see Clinica No 1241, p 13). According to Brian Webster, president of Physio-Control, the Minneapolis, Minnesota-based firm has made "significant investments and improvements" to its technology over the last year. Meanwhile, shipments of the products to non-US customers will continue as normal.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.